228 related articles for article (PubMed ID: 38625038)
1. Proteasome Inhibition Reprograms Chromatin Landscape in Breast Cancer.
Kinyamu HK; Bennett BD; Ward JM; Archer TK
Cancer Res Commun; 2024 Apr; 4(4):1082-1099. PubMed ID: 38625038
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibition reprograms chromatin landscape in breast cancer.
Kinyamu HK; Bennett BD; Ward JM; Archer T
bioRxiv; 2023 Oct; ():. PubMed ID: 37904968
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition creates a chromatin landscape favorable to RNA Pol II processivity.
Kinyamu HK; Bennett BD; Bushel PR; Archer TK
J Biol Chem; 2020 Jan; 295(5):1271-1287. PubMed ID: 31806706
[TBL] [Abstract][Full Text] [Related]
4. Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibition.
Kinyamu HK; Collins JB; Grissom SF; Hebbar PB; Archer TK
Mol Carcinog; 2008 Nov; 47(11):845-85. PubMed ID: 18381591
[TBL] [Abstract][Full Text] [Related]
5. The proteasome inhibitor bortezomib induces an inhibitory chromatin environment at a distal enhancer of the estrogen receptor-α gene.
Powers GL; Rajbhandari P; Solodin NM; Bickford B; Alarid ET
PLoS One; 2013; 8(12):e81110. PubMed ID: 24339902
[TBL] [Abstract][Full Text] [Related]
6. Proteasome activity modulates chromatin modifications and RNA polymerase II phosphorylation to enhance glucocorticoid receptor-mediated transcription.
Kinyamu HK; Archer TK
Mol Cell Biol; 2007 Jul; 27(13):4891-904. PubMed ID: 17438138
[TBL] [Abstract][Full Text] [Related]
7. Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 (HDAC3) Stabilization and Chromatin Condensation.
Maneix L; Iakova P; Moree SE; Hsu JI; Mistry RM; Stossi F; Lulla P; Sun Z; Sahin E; Yellapragada SV; Catic A
Cancer Res Commun; 2022 Dec; 2(12):1693-1710. PubMed ID: 36846090
[TBL] [Abstract][Full Text] [Related]
8. Prolonged proteasome inhibition cyclically upregulates Oct3/4 and Nanog gene expression, but reduces induced pluripotent stem cell colony formation.
Floyd ZE; Staszkiewicz J; Power RA; Kilroy G; Kirk-Ballard H; Barnes CW; Strickler KL; Rim JS; Harkins LL; Gao R; Kim J; Eilertsen KJ
Cell Reprogram; 2015 Apr; 17(2):95-105. PubMed ID: 25826722
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the NRF1-proteasome axis as a therapeutic target in breast cancer.
Byers HA; Brooks AN; Vangala JR; Grible JM; Feygin A; Clevenger CV; Harrell JC; Radhakrishnan SK
Sci Rep; 2023 Sep; 13(1):15843. PubMed ID: 37739987
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the 26S proteasome blocks progesterone receptor-dependent transcription through failed recruitment of RNA polymerase II.
Dennis AP; Lonard DM; Nawaz Z; O'Malley BW
J Steroid Biochem Mol Biol; 2005 Mar; 94(4):337-46. PubMed ID: 15857753
[TBL] [Abstract][Full Text] [Related]
11. Involvement of Nrf2 in proteasome inhibition-mediated induction of ORP150 in thyroid cancer cells.
Zong ZH; Du ZX; Zhang HY; Li C; An MX; Li S; Yao HB; Wang HQ
Oncotarget; 2016 Jan; 7(3):3416-26. PubMed ID: 26700459
[TBL] [Abstract][Full Text] [Related]
12. Investigation of the eIF2alpha phosphorylation mechanism in response to proteasome inhibition in melanoma and breast cancer cells.
Yerlikaya A; DoKudur H
Mol Biol (Mosk); 2010; 44(5):859-66. PubMed ID: 21090173
[TBL] [Abstract][Full Text] [Related]
13. Wedelolactone Acts as Proteasome Inhibitor in Breast Cancer Cells.
Nehybová T; Šmarda J; Daniel L; Stiborek M; Kanický V; Spasojevič I; Preisler J; Damborský J; Beneš P
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28353647
[TBL] [Abstract][Full Text] [Related]
14. Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors.
Liew PL; Huang RL; Weng YC; Fang CL; Hui-Ming Huang T; Lai HC
Int J Cancer; 2018 Jul; 143(2):355-367. PubMed ID: 29451304
[TBL] [Abstract][Full Text] [Related]
15. GSK-3β signaling determines autophagy activation in the breast tumor cell line MCF7 and inclusion formation in the non-tumor cell line MCF10A in response to proteasome inhibition.
Gavilán E; Sánchez-Aguayo I; Daza P; Ruano D
Cell Death Dis; 2013 Apr; 4(4):e572. PubMed ID: 23559006
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of 1α,25-dihydroxyvitamin D3-dependent chromatin accessibility of early vitamin D receptor target genes.
Seuter S; Pehkonen P; Heikkinen S; Carlberg C
Biochim Biophys Acta; 2013 Dec; 1829(12):1266-75. PubMed ID: 24185200
[TBL] [Abstract][Full Text] [Related]
17. FACT and the proteasome promote promoter chromatin disassembly and transcriptional initiation.
Ransom M; Williams SK; Dechassa ML; Das C; Linger J; Adkins M; Liu C; Bartholomew B; Tyler JK
J Biol Chem; 2009 Aug; 284(35):23461-71. PubMed ID: 19574230
[TBL] [Abstract][Full Text] [Related]
18. Proteasomal inhibition enhances glucocorticoid receptor transactivation and alters its subnuclear trafficking.
Deroo BJ; Rentsch C; Sampath S; Young J; DeFranco DB; Archer TK
Mol Cell Biol; 2002 Jun; 22(12):4113-23. PubMed ID: 12024025
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.
Powers GL; Ellison-Zelski SJ; Casa AJ; Lee AV; Alarid ET
Oncogene; 2010 Mar; 29(10):1509-18. PubMed ID: 19946334
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin Disrupts Proteasome Bounce-Back Effect through Suppressing ZEB1/Nfe2l1 in Cholangiocarcinoma.
Xiang Y; Jia M; Gao Y; Yang F; Wang T; Dai R; Wang M; Miao H
Front Biosci (Landmark Ed); 2024 Mar; 29(3):106. PubMed ID: 38538281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
